Mylan's generic Sovaldi launches in India

Mylan's generic version of Sovaldi (sofosbuvir) launched in India under the name MyHep.

The company said in a statement that the sales force from its Hepato Care division is promoting the hepatitis-C medication under a nonexclusive 2014 agreement with Gilead Sciences that allows the generics maker to produce and distribute 400mg tablets of the drug in 91 developing countries. The Hepato division includes women's health, cancer and HIV medications.

Sovaldi's $1,000-per-tablet cost triggered an uproar among insurers in the US. Insurers there fought for discounts by negotiating formulary status with Gilead or by opting to give AbbVie's Viekira Pak preferred status in exchange for a deal.

Mylan has the right to produce generic Sovaldi with drugmakers including Cipla, which launched its version in India last month. Bloomberg News reported in March that Incepta Pharmaceuticals launched an unlicensed version of the drug last month at a cost of around $10 per pill.